Another retrospective study indicated that anti-PD1 antibodies appear more effective and well tolerated in elderly (≥ 75 years old) patients with advanced melanoma than in younger patients [160], but these experiments did not conduct strict age-treatment subgroup analysis. Here, PDCD1 is linked to melanoma.